Biota Pharmaceuticals to Host Conference Call to Report Fourth Quarter and
Fiscal Year-End 2013 Financial Results on September 18, 2013
ATLANTA, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc.
(Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will
host a conference call on Wednesday, September 18, 2013 at 9:00a.m. EDT to
review the Company's fourth quarter and fiscal year-end 2013 financial results
and provide an update on recent corporate developments. The Company will issue
a press release regarding its financial results on the same day, prior to the
To access the conference call, please dial (877) 312-5422 (domestic) or (253)
237-1122 (international). A live audio webcast of the call and the archived
webcast will be available in the Investors section of the Biota website at
Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
discovery and development of products to prevent and treat serious and
potentially life-threatening infectious diseases. The Company currently has
two Phase 2 clinical-stage product candidates in development: Laninamivir
octanoate, which the Company is developing for the treatment of influenza A
and B infections in the U.S. through a contract with the U.S. Office of
Biomedical Advanced Research and Development Authority (BARDA) that provides
up to $231 million in financial support to complete its clinical development;
and vapendavir, a potent, oral broad spectrum capsid inhibitor of
enteroviruses, including human rhinovirus. In addition to these clinical-stage
programs, the Company has preclinical programs focused on developing
treatments for respiratory syncytial virus and gram-negative, multi-drug
resistant bacterial infections. For additional information about the Company,
please visit www.biotapharma.com.
Biota is a registered trademark of Biota Holdings Limited.
CONTACT: Biota Pharmaceuticals, Inc.
Russell H. Plumb, 678-221-3351
President & CEO
Biota Pharmaceuticals, Inc
Press spacebar to pause and continue. Press esc to stop.